LS ARK Genomic Revolution Tracker ETP Securities
ETFs & Funds · EUR · LSE
Price
€2.343
Cap
—
Earnings
—
30d Trend
+14.1%
40% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 53×Macro 0.99 (−1%)=52
RISK
MOMENTUM
TECHNICAL
FUND QUALITY
COST EFFICIENCY
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Short-term opportunity — technical setup
BRAIN47'S ASSESSMENT
I rate LS ARK Genomic Revolution Tracker ETP Securities at 52/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 68/100. I classify this as a growth position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
+9.0%
3 MONTHS
+8.3%
12 MONTHS
+45.3%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Short-term opportunity — technical setup. Momentum (68) and Technical (63) are the primary strengths. I note that cost efficiency is the weakest area at 40/100 — this warrants monitoring. Historical volatility is elevated at 40%. I classify this as a growth position — strong momentum combined with growth potential points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.